• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CALCITRIOL Drug Record

  • Summary
  • Interactions
  • Claims
  • CALCITRIOL chembl:CHEMBL846 ApprovedAntineoplastic

    Alternate Names:

    DIHYDROXYCHOLECALCIFEROL
    DIHYDROXYVITAMIN D 3
    TOPITRIOL
    RO-21-5535
    SILKIS
    1ALPHA,25-DIHYDROXYCHOLECALCIFEROL
    ROCALTROL
    1ALPHA,25-DIHYDROXYVITAMIN D3
    CALCIJEX
    VECTICAL
    RO-215535
    CALCITRIOL
    DECOSTRIOL
    (1Α,3Β,5Z,7E)-9,10-SECOCHOLESTA-5,7,10(19)-TRIENE-1,3,25-TRIOL
    1,25-DIHYDROXYCHOLECALCIFEROL
    1A,25-(OH)2D3
    1ALPHA,25(OH)2D3
    1,25-DIHYDROXYVITAMIN D3
    5-{2-[1-(5-HYDROXY-1,5-DIMETHYL-HEXYL)-7A-METHYL-OCTAHYDRO-INDEN-4-YLIDENE]-ETHYLIDENE}-4-METHYLENE-CYCLOHEXANE-1,3-DIOL
    1Α,25(OH)2D3
    25-DIHYDROXYCHOLECALCIFEROL
    1A,25-DIHYDROXYCHOLECALCIFEROL
    SOLTRIOL
    1,25-DIHYDROXYVITAMIN D
    1-ALPHA,25-DIHYDROXYVITAMIN D3
    1,25-DHCC
    (5Z,7E)-(1S,3R)-9,10-SECOCHOLESTA-5,7,10(19)-TRIENE-1,3,25-TRIOL
    RO 21-5535
    1A,25-DIHYDROXYVITAMIN D3
    (1S,3R,5Z,7E)-9,10-SECOCHOLESTA-5,7,10-TRIENE-1,3,25-TRIOL
    (1R,3S,5Z)-5-{2-[(1R,3AS,4E,7AR)-1-[(2R)-6-HYDROXY-6-METHYLHEPTAN-2-YL]-7A-METHYL-OCTAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE}-4-METHYLIDENECYCLOHEXANE-1,3-DIOL
    DIHYDROXYVITAMIN D3
    1Α,25-DIHYDROXYCHOLECALCIFEROL
    TOPTRIOL
    1,25 DIHYDROXYCHOLECALCIFEROL
    (1ALPHA,3BETA,5Z,7E)-9,10-SECOCHOLESTA-5,7,10(19)-TRIENE-1,3,25-TRIOL
    1-ALPHA-25-DIHYDROXYVITAMIN D3
    CALCIJEX®
    1Α,25-DIHYDROXYVITAMIN D3
    ROCALTROL®
    CALCITRIOLUM
    (3B,5Z,7E)-9,10-SECOCHOLESTA-5,7,10(19)-TRIENETRIOL
    chemidplus:32222-06-3
    drugbank:00136
    chembl:CHEMBL846
    rxcui:1894
    pubchem.compound:5280453

    Drug Info:

    Drug Indications antineoplastic agent
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antipsoriatic agent
    Drug Class antiosteoperosis agent
    Year of Approval 1978
    Drug Class antihypocalcemic agents
    (4 More Sources)

    Publications:

    Ames SK et al., 1999, Vitamin D receptor gene Fok1 polymorphism predicts calcium absorption and bone mineral density in children., J Bone Miner Res
    Yamamoto H et al., 1999, The caudal-related homeodomain protein Cdx-2 regulates vitamin D receptor gene expression in the small intestine., J Bone Miner Res
    Haussler MR et al., 1977, Basic and clinical concepts related to vitamin D metabolism and action (first of two parts)., N Engl J Med
    Creatsa M et al., 2011, The effect of vitamin D receptor BsmI genotype on the response to osteoporosis treatment in postmenopausal women: a pilot study., J Obstet Gynaecol Res
    Senel E et al., 2011, Painful purple plaques on the thighs of an immunosuppressed patient., Clin Exp Dermatol
    Elnenaei MO et al., 2011, Genomic and metabolomic patterns segregate with responses to calcium and vitamin D supplementation., Br J Nutr
    Ryan C et al., 2010, Clinical and genetic predictors of response to narrowband ultraviolet B for the treatment of chronic plaque psoriasis., Br J Dermatol
    Lambrinoudaki I et al., 2011, BsmI vitamin D receptor's polymorphism and bone mineral density in men and premenopausal women on long-term antiepileptic therapy., Eur J Neurol
    Arabi A et al., 2009, Vitamin D receptor gene polymorphisms modulate the skeletal response to vitamin D supplementation in healthy girls., Bone
    Jehan F et al., 2008, Vitamin D receptor genotype in hypophosphatemic rickets as a predictor of growth and response to treatment., J Clin Endocrinol Metab
    Hubner RA et al., 2008, Dairy products, polymorphisms in the vitamin D receptor gene and colorectal adenoma recurrence., Int J Cancer
    Dayangac-Erden D et al., 2007, Polymorphisms of vitamin D receptor gene in Turkish familial psoriasis patients., Arch Dermatol Res
    van Etten E et al., 2007, The vitamin D receptor gene FokI polymorphism: functional impact on the immune system., Eur J Immunol
    d'Alésio A et al., 2005, Two single-nucleotide polymorphisms in the human vitamin D receptor promoter change protein-DNA complex formation and are associated with height and vitamin D status in adolescent girls., Hum Mol Genet
    Abrams SA et al., 2005, Vitamin D receptor Fok1 polymorphisms affect calcium absorption, kinetics, and bone mineralization rates during puberty., J Bone Miner Res
    Halsall JA et al., 2005, Vitamin D receptor gene polymorphisms, particularly the novel A-1012G promoter polymorphism, are associated with vitamin D3 responsiveness and non-familial susceptibility in psoriasis., Pharmacogenet Genomics
    Morrison NA et al., 2005, Vitamin D receptor genotypes influence the success of calcitriol therapy for recurrent vertebral fracture in osteoporosis., Pharmacogenet Genomics
    Palomba S et al., 2005, BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial., Osteoporos Int
    Roth DE et al., 2004, Association between vitamin D receptor gene polymorphisms and response to treatment of pulmonary tuberculosis., J Infect Dis
    International HapMap Consortium., 2003, The International HapMap Project., Nature
    Arai H et al., 2001, The polymorphism in the caudal-related homeodomain protein Cdx-2 binding element in the human vitamin D receptor gene., J Bone Miner Res
    Jurutka PW et al., 2000, The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB., Mol Endocrinol
    Glorieux et al., 2001, The anti-proliferative effect of calcitriol on HL-60 cells is neutralized by uraemic biological fluids., Nephrol. Dial. Transplant.
    Belorusova AY et al., 2014, Structural insights into the molecular mechanism of vitamin D receptor activation by lithocholic acid involving a new mode of ligand recognition., J Med Chem
    Laverny G et al., 2009, Synthesis and anti-inflammatory properties of 1alpha,25-dihydroxy-16-ene-20-cyclopropyl-24-oxo-vitamin D3, a hypocalcemic, stable metabolite of 1alpha,25-dihydroxy-16-ene-20-cyclopropyl-vitamin D3., J Med Chem
    Wongmayura A et al., 2012, Novel vitamin D receptor ligands bearing a spherical hydrophobic core structure--comparison of bicyclic hydrocarbon derivatives with boron cluster derivatives., Bioorg Med Chem Lett
    Lamblin M et al., 2010, An o-aminoanilide analogue of 1α,25-dihydroxyvitamin D(3) functions as a strong vitamin D receptor antagonist., J Med Chem
    Lamblin M et al., 2010, Vitamin D receptor agonist/histone deacetylase inhibitor molecular hybrids., Bioorg Med Chem
    Reinhart, 2004, Vitamin D analogs: novel therapeutic agents for cardiovascular disease?, Curr Opin Investig Drugs
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Dossing et al., 2005, Receptor activator of NF-kappaB ligand protein expression in UMR-106 cells is differentially regulated by parathyroid hormone and calcitriol., J. Cell. Biochem.
    Gyetko et al., 1988, Modulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression by U-937 mononuclear phagocytes. Effects of 1 alpha, 25-dihydroxyvitamin D3 and phorbol ester., J. Immunol.
    Nazarova et al., 2004, Calcitriol-induced prostate-derived factor: autocrine control of prostate cancer cell growth., Int. J. Cancer
    Dackiw et al., 2004, Vitamin D3 administration induces nuclear p27 accumulation, restores differentiation, and reduces tumor burden in a mouse model of metastatic follicular thyroid cancer., Endocrinology
    Ferla S et al., 2014, Small-molecule inhibitors of 25-hydroxyvitamin D-24-hydroxylase (CYP24A1): synthesis and biological evaluation., J Med Chem
    Kruse et al., 1998, Calcium metabolism and growth during early treatment of children with X-linked hypophosphataemic rickets., Eur. J. Pediatr.
    Haq, 1986, 1,25-Dihydroxyvitamin D3 (calcitriol) suppresses IL-2 induced murine thymocyte proliferation., Thymus
    Saunders et al., 1993, Inhibition of c-myc in breast and ovarian carcinoma cells by 1,25-dihydroxyvitamin D3, retinoic acid and dexamethasone., Anticancer Drugs
    Beer et al., 2004, Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy., Cancer Epidemiol. Biomarkers Prev.
  • CALCITRIOL   PHEX

    Interaction Score: 11.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9835432


    Sources:
    NCI

  • CALCITRIOL   CYP24A1

    Interaction Score: 2.81

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25148392


    Sources:
    DTC

  • CALCITRIOL   BTF3P11

    Interaction Score: 2.81

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15849738


    Sources:
    NCI

  • CALCITRIOL   GDF15

    Interaction Score: 2.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15386353


    Sources:
    NCI

  • CALCITRIOL   TG

    Interaction Score: 0.62

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15319350


    Sources:
    NCI

  • CALCITRIOL   VDR

    Interaction Score: 0.45

    Interaction Types & Directionality:
    agonist (activating)
    antagonist (inhibitory)

    Interaction Info:
    Trial Name DN-101,Asentar
    Novel drug target Established target
    Trial Name calcitriol, vitamin D3 derivative,Silkis, Vectical

    PMIDs:
    10320522 9933478 333287 21651652 21418277 20727239 20716226 20500803 19647104 18827005 18470879 17763859 17274004 16210379 15883634 15864137 15861036 15739035 15295697 14685227 11450701 10707958 11158396 24818857 19309155 22285943 20883026 20452225 15503649 11752352


    Sources:
    DTC TdgClinicalTrial ChemblInteractions NCI TEND PharmGKB TTD

  • CALCITRIOL   PLAU

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    3139763


    Sources:
    NCI

  • CALCITRIOL   MYC

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8490200 15598784


    Sources:
    NCI

  • CALCITRIOL   IL2

    Interaction Score: 0.35

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    3492067


    Sources:
    NCI

  • CALCITRIOL   GMNN

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CALCITRIOL   AR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: CALCITRIOL

    • Version: 01-August-2011

    Alternate Names:
    CALCITRIOL Primary Drug Name

    Drug Info:
    Drug Class antihypocalcemic agents
    Year of Approval 1978
    Drug Class antiosteoperosis agent

    Publications:

  • TdgClinicalTrial: CALCITRIOL

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antipsoriatic agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • DTC: CALCITRIOL

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL846 ChEMBL Drug ID

    Drug Info:

    Publications:
    Ferla S et al., 2014, Small-molecule inhibitors of 25-hydroxyvitamin D-24-hydroxylase (CYP24A1): synthesis and biological evaluation., J Med Chem
    Wongmayura A et al., 2012, Novel vitamin D receptor ligands bearing a spherical hydrophobic core structure--comparison of bicyclic hydrocarbon derivatives with boron cluster derivatives., Bioorg Med Chem Lett
    Laverny G et al., 2009, Synthesis and anti-inflammatory properties of 1alpha,25-dihydroxy-16-ene-20-cyclopropyl-24-oxo-vitamin D3, a hypocalcemic, stable metabolite of 1alpha,25-dihydroxy-16-ene-20-cyclopropyl-vitamin D3., J Med Chem

  • NCI: CALCITRIOL

    • Version: 14-September-2017

    Alternate Names:
    C330 NCI drug code

    Drug Info:

    Publications:
    Nazarova et al., 2004, Calcitriol-induced prostate-derived factor: autocrine control of prostate cancer cell growth., Int. J. Cancer
    Kruse et al., 1998, Calcium metabolism and growth during early treatment of children with X-linked hypophosphataemic rickets., Eur. J. Pediatr.
    Dackiw et al., 2004, Vitamin D3 administration induces nuclear p27 accumulation, restores differentiation, and reduces tumor burden in a mouse model of metastatic follicular thyroid cancer., Endocrinology

  • PharmGKB: calcitriol

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Abrams SA et al., 2005, Vitamin D receptor Fok1 polymorphisms affect calcium absorption, kinetics, and bone mineralization rates during puberty., J Bone Miner Res
    Hubner RA et al., 2008, Dairy products, polymorphisms in the vitamin D receptor gene and colorectal adenoma recurrence., Int J Cancer
    van Etten E et al., 2007, The vitamin D receptor gene FokI polymorphism: functional impact on the immune system., Eur J Immunol

  • TTD: Calcitriol

    • Version: 2020.06.01

    Alternate Names:
    D0T2PL TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL846

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL846

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21